What Medkoo Biosciences does

MedKoo Biosciences, Inc. is a US-based specialty supplier of small molecule research drugs and biochemical reagents founded in 2009 by Dr. Qingqi Chen and headquartered in the Research Triangle Park area of Durham, North Carolina. The company operates a catalogue of more than 7,000 research-grade compounds spanning approved drugs, discontinued drugs, drug candidates, inhibitors, agonists, fluorescent probes, and imaging agents across 25+ research areas, supplemented by a structured service portfolio that includes custom organic synthesis (with stated capacity of 300-400 complex compounds per year), process research and development, antibody-drug conjugation, bioconjugate and diagnostic bioconjugate synthesis, and hapten design. The company emphasizes a 100% quality guarantee backed by NMR, HPLC, and MS testing on every batch and has secured exclusive inbound licences on eight academic tool compounds from Vanderbilt, Tohoku, NYU/Pittsburgh, and University of Florida between 2024 and 2025.

The business model combines catalog sales (unit-priced per mg, gram, or bulk quantity) with project-priced custom synthesis engagements (minimum 1g order), plus CRO-style services in conjugation and process development. Products are sold exclusively for research use; no GMP, DMF, ISO, or DEA certifications are claimed. Distribution runs through direct e-commerce on medkoo.com (with same-day shipping from the Durham warehouse), offline purchase orders via email/fax/phone with Net 30 terms for qualified buyers, and an international distributor network. Marketing relies on the website, organic social media, downloadable technical catalogues, peer-reviewed journal citations (products cited in Nature, Cell, Nat Commun, Nat Biotechnol, and Nat Chem Biol), and trade shows.

Customer segments span academic research institutions, biotechnology companies, pharmaceutical companies, and biomedical research institutions. MedKoo has been awarded NIH biomedical research contracts in September 2021 (75N95021P00528) and September 2022 (75N95022P00731). The company remains privately held, founder-led, and operates with a disclosed headcount of 1-10 employees, with no external private equity or venture capital involvement identified in the available data. Revenue is not publicly disclosed.

Name

Medkoo Biosciences

Legal name

MedKoo Biosciences, Inc.

Website

https://medkoo.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

1–10 employees

Short description

MedKoo Biosciences is a privately held US supplier of 7,000+ small molecule research compounds and custom synthesis services, serving academic, biotech, pharmaceutical, and biomedical research laboratories through direct e-commerce and CRO engagements.

Ownership category

akta.pro rank

Product category

Research-Grade Biochemical Reagents

NAICS

Scientific Research and Development Services (5417), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Services-Commercial Physical & Biological Research (8731), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

akta.pro secondary industries

Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD), DMPK / ADME & Bioanalysis (HLAGAFAC)

Keywords

• Biochemical reagents supplier
• Small molecule drugs
• Custom organic synthesis
• Kinase inhibitors
• Research chemicals catalog

Headquarters

HQ city

Morrisville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Product Sales: Sale of biochemical reagents and small molecule drugs for laboratory research use. Products range from milligrams to kilograms with unit-based pricing.
2. Custom Synthesis Services: Custom organic synthesis services for complex, hard-to-source compounds. Minimum order 1g. Pricing and lead time vary by compound complexity.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

MedKoo Biosciences supplies a catalog of more than 7,000 research-grade small molecule drugs, kinase inhibitors, biochemical reagents, fluorescent probes, and imaging agents for laboratory research. The company also offers fee-based custom organic synthesis, process research and development, antibody-drug conjugation, bioconjugate synthesis, diagnostic bioconjugate development, and hapten design services, shipping worldwide from its Durham, NC warehouse.

Product overview

Medkoo Biosciences operates as a supplier of high-quality biochemical reagents specializing in small molecule drugs for laboratory research. The core offering consists of an extensive catalog of small molecule research compounds with related chemical information (CAS numbers, purity data, QC documentation). The portfolio includes custom synthesis services (capable of producing 300-400 complex compounds annually), process research and development, antibody-drug conjugation, bioconjugate synthesis, diagnostic bioconjugate development, and hapten design services. The company also provides supporting tools including a drug synthesis database, structure search functionality, and online ordering platform. All products are for research use only, not for human or veterinary use.

Differentiator

Problem solved

Functional benefit

Products and services

• Small Molecule Research Drugs Catalog Catalog of high-quality biochemical reagents and small molecule drugs for laboratory research use, covering approved drugs, discontinued compounds, drug candidates, kinase inhibitors, agonists, fluorescent probes, and imaging agents for academic, biotechnology, biomedical, and pharmaceutical researchers.
• Custom Synthesis Custom organic synthesis services including synthesis of drug candidates, reference compounds, newly published compounds, synthetic route design, process development, and bulk quantity manufacturing, with a 1g minimum order and the capability to produce 300–400 complex compounds per year.
• Process Research & Development CRO service for scalable process identification including process characterization and validation, reaction optimization, catalyst screening, crystallization studies, salt selection and polymorph screening, impurity profiling, and API synthesis for GLP toxicology through clinical studies.
• Antibody Drug Conjugation Site-specific antibody-drug conjugation services using traditional and proprietary conjugation strategies, linking drugs or toxins to antibodies with characterization by SEC and UV/Vis spectrometry for targeted cancer therapy applications.
• Bioconjugate Synthesis Custom bioconjugation and labeling services including infrared and visible dye labeling for antibodies, proteins, peptides, enzymes, small molecules, lectins, polymers, and nanoparticles, with derivatization chemistries including NHS Ester, Maleimide, Azide, Alkyne, DBCO, Hydrazide, and Amine.
• Diagnostic Bioconjugates Portfolio of bioconjugates for diagnostic and medical imaging companies, including peptide-macrocyclic metal conjugates, antibody-luminex bead conjugates, oligonucleotide conjugates, enzyme-based bioconjugates, and microsphere/nanosphere conjugates.
• Hapten Design and Synthesis Design and synthesis of haptens for immunoassay development, including linker attachment positioning, total synthesis, linker length design, and drug-to-carrier protein ratio control, with 20 years of experience in small molecule antibody development.

Quantifiable outcome

• 100% quality guarantee on all products with NMR, HPLC, MS analysis
• +2 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators4 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• Tocris Bioscience (Bio-Techne): Tocris supplies small-molecule research tools, inhibitors, and tool compounds to academic and pharma researchers—directly overlapping with MedKoo's catalog of kinase inhibitors, agonists, and reference compounds. As a Bio-Techne brand, it shares the same research-use, lab-bench customer base.
• Cayman Chemical: Cayman is a leading supplier of biochemical reagents, antibodies, and small-molecule research compounds serving academic and pharma research. Its catalog breadth, custom synthesis capabilities, and immunoassay/hapten offerings are directly comparable to MedKoo's portfolio.
• Selleck Chemicals: Selleck is a specialty supplier of small-molecule inhibitors, particularly in oncology, with a deep catalog of FDA-approved and clinical-stage compounds. Its positioning as a kinase-inhibitor-focused supplier maps closely to MedKoo's anticancer reagent focus.
• MedChemExpress (MCE): MCE is a fast-growing global supplier of small-molecule inhibitors, reference compounds, and biochemical reagents with strong e-commerce and international logistics. It directly competes with MedKoo across kinase inhibitors, tool compounds, and natural product derivatives.
• Santa Cruz Biotechnology: Santa Cruz Biotechnology supplies antibodies, biochemical reagents, and small-molecule research compounds to academic and biotech researchers. Its catalog breadth and research-use-only positioning closely parallel MedKoo's go-to-market.
• TCI Chemicals: TCI is a global manufacturer of fine chemicals, organic intermediates, and research reagents with extensive catalog coverage. Its custom synthesis and bulk manufacturing services overlap directly with MedKoo's process R&D and custom synthesis offerings.
• BOC Sciences: BOC Sciences is a custom synthesis CRO and biochemical reagent supplier offering reference compounds, intermediates, and process R&D services. Its e-commerce catalog and project-based custom synthesis directly overlap with MedKoo's hybrid product/service model.
• Enamine: Enamine is a leading supplier of screening compounds, building blocks, and custom synthesis services for drug discovery. Its chemical catalog and on-demand custom synthesis capabilities are directly comparable to MedKoo's research compound offering.
• Biosynth (formerly Carbosynth): Biosynth supplies biochemicals, carbohydrates, nucleosides, and life-science reagents with a focus on catalog and custom synthesis. Its reagent-and-services mix and research-use customer base align closely with MedKoo's positioning.

Broad incumbents

• Sigma-Aldrich (Merck): Sigma-Aldrich (Merck KGaA/MilliporeSigma) is the dominant global biochemical reagent supplier with massive catalog depth, GMP capabilities, and global distribution. It competes with MedKoo across virtually all reagent categories but at vastly greater scale and breadth.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/medkoobio
• LinkedInlinkedin.com/company/medkoo-biosciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medkoo Biosciences